Daebong LS

New salt improved drug and innovative manufacturing method. Manufacturing method of Azilsartan using eco-friendly solvents. License to implement the manufacturing method based on patents. - Technology transfer with patent

First-in-the world oral delivery system for antifungal therapies, designed for improved, dosing and patient convenience. Global patents. S. Korea, Japan, China, US, EU, and India - covering composition, manufacturing method, sustainable production, and formulation. - Technology transfer with patent

The next generation Mucolytic and Antioxidant solution. - Powerful mucolytic action. - Potent Antioxidant properties - Comprehensive therapeutic effects - An effective solution for various respiratory conditions Technology transfer with patent

Daebong LS is pleased to announce its participation in CPhI Frankfurt 2025 on October 28th, where the company will engage in a series of B2B meetings with global partners.

During the event, Daebong LS will highlight its latest research achievements, including:
Efinaconazole Co-crystal
L-Erdosteine
Novel Salt of Azilsartan

Through these presentations, Daebong LS aims to explore opportunities for technology transfer and strengthen collaborations with leading companies in the pharmaceutical industry.

As an active developer of innovative active pharmaceutical ingredients (APIs), Daebong continues to expand its global partnerships and contribute to advancing healthcare solutions.

New R&D Center in Songdo